Moving onto Solids
CAR T therapy – where the T cells of a cancer patient's immune system are genetically engineered to recognise and kill tumour cells – is transforming the treatment of 'liquid' cancers (such as leukaemia, lymphoma and myeloma). Its application for solid tumours, however, hasn't been straightforward. But that may be set to change as a fitting target for CAR T therapy against solid cancer has now been identified – a molecule called urokinase plasminogen activator receptor
Image made using Leica Microsystems Cell DIVE multiplex imaging
Read the published research article here
Image from work by Zeda Zhang and colleagues
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Image originally published with a Creative Commons Attribution 4.0 International (CC BY 4.0)
Published in Cell, March 2026
You can also follow BPoD on Instagram, Twitter, Facebook and Bluesky